Table 1 Clinicopathologic characteristics.
From: Added prognostic value of temporal muscle thickness in glioblastoma with age-stratified analysis
Non-sarcopenic (n = 209) | Sarcopenic (n = 76) | Total (n = 285) | |
|---|---|---|---|
TMT (mm) | 9.37 (7.26–15.1) | 6.32 (3.28–7.24) | 8.59 (3.28–15.1) |
Sex | |||
Male | 112 (53.6%) | 45 (59.2%) | 157 (55.1%) |
Female | 97 (46.4%) | 31 (40.8%) | 128 (44.9%) |
AGE (yr) | 57.5 (20–87) | 62.8 (29–85) | 58.8 (20–87) |
KPS | 85.2 (30–100) | 83.8 (45–100) | 84.8 |
mMGMT | |||
(+) | 92 (44.0%) | 29 (38.2%) | 121 (42.5%) |
(-) | 117 (56.0%) | 47 (61.8%) | 164 (57.5%) |
PTEN mutation | |||
(+) | 21 (10.0%) | 6 (7.9%) | 27 (9.5%) |
(-) | 188 (90.0%) | 70 (92.1%) | 258 (90.5%) |
EGFR gene amplification | |||
(+) | 69 (33.0%) | 26 (34.2%) | 95 (33.3%) |
(-) | 140 (67.0%) | 50 (65.8%) | 190 (67.7%) |
TERTp mutation | |||
(+) | 58 (27.8%) | 25 (32.9%) | 83 (29.1%) |
(-) | 151 (72.2%) | 51 (67.1%) | 202 (70.9%) |
EOR | |||
GTR | 150 (71.8%) | 53 (69.7%) | 203 (71.2%) |
Non-GTR | 59 (28.2%) | 23 (30.3%) | 82 (28.8%) |
Median OS (day) | 826 (IQR: 631–1046) | 625 (IQR: 466–787) | 775(IQR: 581–982) |
